FindTrial
Sign In

20 mg/ml

DRUG2 trials

Sponsors

AstraZeneca AB, Instytut Hematologii I Transfuzjologii

Conditions

Advanced/Metastatic Gastric cancerDiffuse large B-cell lymphoma) and aggressive B-cell lymphomas (HGBCLDiffuse large B-cell lymphomas (DLBCLGastric cancerGastroesophageal Junction Adenocarcinoma Expressing Claudin18.2High-grade B-cell lymphoma) originate from mature B-cells at various stages of terminal differentiation

Phase 2

A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/HGBCL relapse
Not yet recruitingCTIS2024-518275-64-00
Instytut Hematologii I TransfuzjologiiDiffuse large B-cell lymphoma) and aggressive B-cell lymphomas (HGBCL, Diffuse large B-cell lymphomas (DLBCL, High-grade B-cell lymphoma) originate from mature B-cells at various stages of terminal differentiation
Target: 340Updated: 2025-11-24

Phase 3

A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin 18.2 (CLARITY-Gastric 01)
RecruitingCTIS2023-508276-11-00
AstraZeneca ABAdvanced/Metastatic Gastric cancer, Gastric cancer, Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Start: 2025-01-17Target: 91Updated: 2025-09-15